Robert W. Duggan joined the Board of Directors in December 2019 and has been the Executive Chairman our Board since February 2020. Mr. Duggan has served as our Chief Executive Officer since April 2020.
Since 2015, Mr. Duggan has also been the Founder and CEO of Duggan Investments, a venture capital and equity investment firm. His firm’s investments primarily focus on patient-friendly breakthrough solutions to complex diseases of aging.
From 2008 to 2015, Mr. Duggan was Chairman, CEO, and the largest investor in Pharmacyclics, Inc., a patient-friendly, science-based, employee-driven developer of small-molecule medicines for the treatment of certain cancers. Mr. Duggan led both the multimillion-dollar collaboration and license deal for ibrutinib (later marketed as IMBRUVICA®) with Johnson & Johnson in 2011, and the subsequent sale of Pharmacyclics to AbbVie Inc. in 2015. The acquisition of Pharmacyclics by AbbVie for approximately $21B remains one of the largest transactions to have occurred in the pharmaceutical and biotechnology industries.
From 1990 to 2003, Mr. Duggan was Chairman of the Board of Directors of Computer Motion, Inc., a groundbreaking robotic surgery company that helped change the way in which many surgical procedures are performed around the world with the assistance of its minimally invasive, robotics-based surgical systems. From 1997 to 2003, Mr. Duggan also served as CEO of Computer Motion. In June 2003, Computer Motion merged with Intuitive Surgical, Inc. From the completion of the merger in 2003 until 2011, Mr. Duggan served on the Board of Directors of Intuitive Surgical.
Mr. Duggan received a US Congressional Medal of Merit from Congressman Dr. Ron Paul in 1985. In 2000, he was named a Knight of the Legion D’Honor by President Jacques Chirac of France.
Beyond Summit, Mr. Duggan is currently the Chairman of the Board at Pulse BioSciences, Inc., and is also a member of the University of California at Santa Barbara Foundation Board of Trustees. Mr. Duggan has also funded two Chairs in Mathematical, Life, and Physical Sciences, as well as a Chair in Religious Studies at the University of California at Santa Barbara.
What is Robert W. Duggan's net worth?
The estimated net worth of Robert W. Duggan is at least $790.34 million as of December 11th, 2023. Mr. Duggan owns 36,966,180 shares of Summit Therapeutics stock worth more than $790,336,928 as of November 12th. This net worth evaluation does not reflect any other investments that Mr. Duggan may own. Learn More about Robert W. Duggan's net worth.
How old is Robert W. Duggan?
How do I contact Robert W. Duggan?
Has Robert W. Duggan been buying or selling shares of Summit Therapeutics?
Robert W. Duggan has not been actively trading shares of Summit Therapeutics during the last quarter. Most recently, on Monday, March 6th, Robert W. Duggan bought 376,489,880 shares of Summit Therapeutics stock. The stock was acquired at an average cost of $1.05 per share, with a total value of $395,314,374.00. Following the completion of the transaction, the chief executive officer now directly owns 552,354,161 shares of the company's stock, valued at $579,971,869.05. Learn More on Robert W. Duggan's trading history.
Who are Summit Therapeutics' active insiders?
Are insiders buying or selling shares of Summit Therapeutics?
In the last year, Summit Therapeutics insiders bought shares 4 times. They purchased a total of 155,400 shares worth more than $542,118.00. The most recent insider tranaction occured on March, 26th when CEO Mahkam Zanganeh bought 30,000 shares worth more than $112,500.00. Insiders at Summit Therapeutics own 88.3% of the company.
Learn More about insider trades at Summit Therapeutics. Information on this page was last updated on 3/26/2024.
